The Max Foundation Delivers First Treatment into Mozambique

The Max Foundation Delivers First Treatment into Mozambique

On November 1, 2019, the first shipment of treatment arrived at the hospital in Maputo, Mozambique. This is the first country Max Access Solutions, The Max Foundation’s patient-centered access model, has expanded into without a former access program in place.

“The Max Access Solutions provides hope in the form of innovative cancer treatment in neglected regions of the world,” says Pat Garcia-Gonzalez, CEO of The Max Foundation. “Today we reached a new frontier and I am deeply grateful to all who made it possible.”

In the beginning of 2018, Cathy Scheepers, The Max Foundation’s Region Head of Africa & Middle East visited the hospital in Maputo and learned of over 100 chronic myeloid leukemia (CML) patients who were unable to access treatment. The only way patients could access treatment was to travel to South Africa, a challenging day of travel. Mozambique is one of the poorest countries in the world, and for the majority of people living there, traveling to find treatment was simply not an option.

“Over 100 patients who have had a five-year life expectancy now have access to live normal lives.” says Cathy. “We’re changing not only the physician and patient perspectives, but also the broader community perspective that cancer is not always a death sentence. There is hope if you have access to treatment.”

Thank you to all who made access to treatment in Mozambique a reality: the passionate donors, physicians in Maputo, Humanitarian PACT partner Novartis, advisors, and The Max Foundation’s global team members. Everyone involved worked tirelessly to expand the scope of Max Access Solutions into the hands of those awaiting treatment, and now, patients have the chance to spend more days with their families, communities, and loved ones.

The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 28 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.

Related Articles

  • Tanner Pharma Group Delivers on “Last Mile” in Global Health

    Tanner Pharma Group Delivers on “Last Mile” in Global Health

    Tanner Pharma Group will serve as the title sponsor for The Max Foundation’s 2018 campaign “Max Global Experience: Uganda,” an expedition to raise awareness and funds for increased cancer treatment access in Africa.

  • The Max Foundation Announces CancerPath to Care to Treat Up to 36,000 People Living with Leukemia, Breast and Certain Rare Cancers in Over 70 Low- and Middle-income Countries by 2025

    The Max Foundation Announces CancerPath to Care to Treat Up to 36,000 People Living with Leukemia, Breast and Certain Rare Cancers in Over 70 Low- and Middle-income Countries by 2025

    New initiative expands existing collaboration with Novartis focused on chronic myeloid leukemia and other rare cancers, to support patient access to care for breast cancer, the leading cause of death in women globally

  • The Max Foundation (Max) and the International PNH Interest Group (IPIG) Announce Collaboration to Improve Care and Management for People Living with Paroxysmal Nocturnal Hemoglobinuria (PNH) in Low-Resource Countries

    The Max Foundation (Max) and the International PNH Interest Group (IPIG) Announce Collaboration to Improve Care and Management for People Living with Paroxysmal Nocturnal Hemoglobinuria (PNH) in Low-Resource Countries

    IPIG joins Max’s Humanitarian Partnership for Access to Critical Treatments (Humanitarian PACT) and will provide medical education and training on PNH care and management Max will provide access to innovative treatment as part of the multi-stakeholder collaboration focused on eradicating survival disparities in 53 low-resource countries People living with this rare blood disease require frequent….